Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-26
DOI
10.1038/s41467-022-31941-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs
- (2022) Mara Gilardi et al. MOLECULAR CANCER THERAPEUTICS
- Interleukin-1 as Innate Mediator of T Cell Immunity
- (2021) Bram Van Den Eeckhout et al. Frontiers in Immunology
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
- (2021) Benjamin Lacas et al. RADIOTHERAPY AND ONCOLOGY
- Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
- (2021) Zhiyong Wang et al. Nature Communications
- Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
- (2021) Rom Leidner et al. Journal for ImmunoTherapy of Cancer
- Head and neck cancer
- (2021) Mayur D Mody et al. LANCET
- Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
- (2021) Hirofumi Shibata et al. Frontiers in Oncology
- Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities
- (2021) Robert Saddawi-Konefka et al. Frontiers in Oncology
- NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity
- (2021) Ghita Ghislat et al. Science Immunology
- Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling
- (2020) Sampath K. Loganathan et al. SCIENCE
- Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
- (2020) Hiroshi Matsuoka et al. BMC CANCER
- The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
- (2020) Nathalie Percie du Sert et al. PLOS BIOLOGY
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
- (2020) David M. Francis et al. Science Translational Medicine
- Head and neck squamous cell carcinoma
- (2020) Daniel E. Johnson et al. Nature Reviews Disease Primers
- Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
- (2019) J. Rogado et al. EUROPEAN JOURNAL OF CANCER
- EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Lisa F. Licitra et al. JOURNAL OF CLINICAL ONCOLOGY
- High-dimensional cell-level analysis of tissues with Ce3D multiplex volume imaging
- (2019) Weizhe Li et al. Nature Protocols
- Functional Organ Preservation Surgery in Head and Neck Cancer: Transoral Robotic Surgery and Beyond
- (2019) Wojciech Golusiński Frontiers in Oncology
- CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention
- (2019) Yan Yan et al. Frontiers in Cell and Developmental Biology
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Chemokine and chemotactic signals in dendritic cell migration
- (2018) Laura Tiberio et al. Cellular & Molecular Immunology
- Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
- (2018) Ariel E. Marciscano et al. CLINICAL CANCER RESEARCH
- A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR
- (2018) L. Siu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
- (2018) Hisham Mehanna et al. LANCET
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Double-slit photoelectron interference in strong-field ionization of the neon dimer
- (2018) Maksim Kunitski et al. Nature Communications
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues
- (2017) D Sichien et al. Mucosal Immunology
- Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
- (2017) Kenji Chamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
- (2017) Adam Diehl et al. Oncotarget
- Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma
- (2017) Paul Zolkind et al. Oncotarget
- Genomic predictive model for recurrence and metastasis development in head and neck squamous cell carcinoma patients
- (2017) Ilda Patrícia Ribeiro et al. Scientific Reports
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation
- (2016) Jernej Godec et al. IMMUNITY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer
- (2015) Anil K. D’Cruz et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
- (2015) Harrison Cash et al. Oncotarget
- Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow
- (2014) C. T. Mayer et al. BLOOD
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Critical Roles of a Dendritic Cell Subset Expressing a Chemokine Receptor, XCR1
- (2013) C. Yamazaki et al. JOURNAL OF IMMUNOLOGY
- Development and validation of a treatment planning system for small animal radiotherapy: SmART-Plan
- (2013) Stefan J. van Hoof et al. RADIOTHERAPY AND ONCOLOGY
- Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer
- (2012) Nancy P. Judd et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Type I interferon response and innate immune sensing of cancer
- (2012) Mercedes B. Fuertes et al. TRENDS IN IMMUNOLOGY
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model
- (2009) R. Czerninski et al. Cancer Prevention Research
- Chemical Carcinogenesis Models for Evaluating Molecular-Targeted Prevention and Treatment of Oral Cancer
- (2009) L. Vitale-Cross et al. Cancer Prevention Research
- Decision analysis and treatment threshold in a management for the N0 neck of the oral cavity carcinoma
- (2009) Masaya Okura et al. ORAL ONCOLOGY
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
- (2009) Jean-Pierre Pignon et al. RADIOTHERAPY AND ONCOLOGY
- Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity
- (2008) K. Hildner et al. SCIENCE
- Lymph node mapping in the mouse
- (2007) Maria I. Harrell et al. JOURNAL OF IMMUNOLOGICAL METHODS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started